Patents for A61P 35 - Antineoplastic agents (221,099)
04/2002
04/30/2002US6379672 Prevention of infectious diseases with gp96-peptide complexes
04/30/2002US6379671 Using a polypeptide antigen mixture
04/30/2002US6379649 Useful for diagnosis and treatment, including radiotherapy, of disorders that are characterized by an abnormal density of peripheral benzodiazepine receptors; nerve system disporders
04/30/2002CA2131761C Crystals of pyridonecarboxylic acid derivative
04/30/2002CA2088931C Phosphonooxy and carbonate derivatives of taxol
04/30/2002CA2020247C Antibodies reactive with human carcinomas
04/26/2002CA2324631A1 A substance or composition for the treatment of cancer
04/25/2002WO2002033116A2 Nucleic acid ligands to the prostate specific membrane antigen
04/25/2002WO2002033101A1 Chimeric cytoplasmic signalling molecules derived from cd137
04/25/2002WO2002033100A2 Regulation of human adenylate cyclase, type iv
04/25/2002WO2002033099A2 Human kinases
04/25/2002WO2002033096A2 Regulation of human serine-threonine protein kinase
04/25/2002WO2002033095A2 Regulation of human serine-threonine protein kinase
04/25/2002WO2002033090A2 Pharmaceutical preparations and methods for inhibiting tumors
04/25/2002WO2002033089A2 Ixodes scapularis tissue factor pathway inhibitor
04/25/2002WO2002033080A2 Regulation of human netrin binding membrane receptor unc5h-1
04/25/2002WO2002033079A2 Human g-protein coupled receptor and uses thereof
04/25/2002WO2002033071A1 Survivin-like polypeptides and dnas thereof
04/25/2002WO2002033050A2 Methods and compositions for promoting the maturation of monocytes
04/25/2002WO2002033044A2 Methods of high-throughput screening for internalizing antibodies
04/25/2002WO2002032961A2 Novel polypeptides and nucleic acids encoding same
04/25/2002WO2002032958A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
04/25/2002WO2002032953A2 Pregnancy-associated plasma protein-a2 (papp-a2)
04/25/2002WO2002032920A2 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
04/25/2002WO2002032904A1 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents
04/25/2002WO2002032901A2 Bridged piperazine derivatives
04/25/2002WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
04/25/2002WO2002032879A1 Dihydropyrimidine derivatives as cysteine protease inhibitors
04/25/2002WO2002032874A2 Substituted heterocyclic compounds for treating multidrug resistance
04/25/2002WO2002032872A1 Nitrogenous aromatic ring compounds
04/25/2002WO2002032871A2 Compounds and methods for treating multidrug resistance
04/25/2002WO2002032869A2 Substituted heterocyclic compounds for treating multidrug resistance
04/25/2002WO2002032868A2 2-substituted heterocyclic compounds and their use in treating multidrug resistance
04/25/2002WO2002032861A2 Orally active salts with tyrosine kinase activity
04/25/2002WO2002032857A1 Methods of producing oxazolidinone compounds
04/25/2002WO2002032507A1 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
04/25/2002WO2002032450A2 Vaccines
04/25/2002WO2002032444A1 Novel medicinal herbal composition for treating liver diseases and hiv
04/25/2002WO2002032432A1 Use of antiprogestins for the induction of apoptosis in a cell
04/25/2002WO2002032430A1 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
04/25/2002WO2002032429A2 Use of inhibitors of progesterone receptor for treating cancer
04/25/2002WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis
04/25/2002WO2002032415A2 Process of making and method of use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa cells
04/25/2002WO2002032413A2 A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
04/25/2002WO2002032409A2 Use of compound in the manufacture of a pharmaceutical for inhibiting steroid sulphatase and steroid dehydrogenase activity
04/25/2002WO2002032404A2 Nanoparticles
04/25/2002WO2002032400A1 Liposomal formulation of mitoxantrone
04/25/2002WO2002032399A1 Taxol liposome composition for treatment of cancer and preparation thereof
04/25/2002WO2002032378A2 Fusion cells and cytokine compositions for treatment of disease
04/25/2002WO2002032377A2 Estrogen receptor modulators
04/25/2002WO2002032373A2 Estrogen receptor modulators
04/25/2002WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
04/25/2002WO2002010191A3 Immunomodulatory compounds
04/25/2002WO2002010137A3 Indazole derivatives as JNK inhibitors
04/25/2002WO2001098506A3 Methods and means for regulation of gene expression
04/25/2002WO2001093805A3 FUSION OF jAZF1 AND jjAZ1 GENES IN ENDOMETIRIAL STROMAL TUMORS
04/25/2002WO2001087283A3 New use of citreamicins
04/25/2002WO2001083740A3 Splice-region antisense composition and method
04/25/2002WO2001081341A3 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations
04/25/2002WO2001081333A3 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
04/25/2002WO2001075072A3 Production of TcR gamma delta T cells
04/25/2002WO2001072831A3 Immunoregulator
04/25/2002WO2001070208A3 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
04/25/2002WO2001068880A3 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use
04/25/2002WO2001062300A3 Caspase activated prodrugs therapy
04/25/2002WO2001061010A3 GTPASE activating proteins
04/25/2002WO2001056552A3 Farnesyl protein transferase inhibitors for treating breast cancer
04/25/2002WO2001052904A3 Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
04/25/2002WO2001047913A3 Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect
04/25/2002WO2001047533A3 INHIBITION OF GSK-3$g(b)
04/25/2002WO2001042471A3 Polypeptides and polynucleotides encoding same
04/25/2002WO2001041810A3 Nucleic acid delivery system
04/25/2002WO2001029193A3 Cell constructs that are suitable for immunotherapy, the production and the use thereof
04/25/2002WO2001028521A3 Liposome formulation of 6,9-bis-[(2-aminoethyl)-amino]benzo[g]isoquinoline-5,10-dione dimaleate
04/25/2002WO2001002369A3 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
04/25/2002US20020049389 Noninvasive measurement of chemical substances
04/25/2002US20020049344 New vitamin d derivatives with carbo-or heterocyclic substituents at c-25, a process for their production, intermediate products and their use for producing medicaments
04/25/2002US20020049335 DNA alkylating compounds such as 1-(tert-butyloxycarbonyl) -4-hydroxy-3(((methane-sulfonyl)oxy)methyl)-2,3-dihydroindole
04/25/2002US20020049327 Such as 7-(3-chlorophenyl)-9-((4-chlorophenyl)-1H-imidazol-1-ylmethyl)-2,3-dihydro -1H,5H-benzo(ij)quinolizin-5-one; for forming oncogenes for signalling transformation of tumor cells
04/25/2002US20020049324 Topoisomerase inhibitors
04/25/2002US20020049301 For therapy of cancer, diabetes, obesity, diseases of the central nervous system, inflammatory disorders, autoimmune dieseases cardiovascular diseases, for generating antibodies
04/25/2002US20020049252 Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid
04/25/2002US20020049248 Alone or in combination for treatment of adult-T-cell leukemia- lymphoma
04/25/2002US20020049247 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes...
04/25/2002US20020049244 Treatment of disease or disease symptoms mediated by eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE) a potent constrictor of renal, cerebral and skeletal muscle arterioles
04/25/2002US20020049243 Pyrrolidine derivatives
04/25/2002US20020049238 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
04/25/2002US20020049233 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
04/25/2002US20020049231 S(-)-3-aminothalidomide; treating wide variety of diseases including diabetic retinopathy
04/25/2002US20020049224 Alpha v integrin receptor antagonists
04/25/2002US20020049220 Substituted azoles
04/25/2002US20020049218 2-, 6, and 9-substituted purine derivatives, particularly 2(1-R hydroxymethylpropylamino)-6-benzylamino-9-isopropyl purine, used as drug and herbicide; inhibiting effect with respect to cyclin-dependent kinase proteins
04/25/2002US20020049217 Peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras
04/25/2002US20020049215 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
04/25/2002US20020049214 Aralkyl and aralkylidene heterocyclic lactams and imides as selective agonists and antagonists of serotonin 1 (5-HT1) recepor, used in treating hypertension and all forms of depression
04/25/2002US20020049204 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma
04/25/2002US20020049202 Administering halogenated amidino or oxyamidino compound to treat diseases caused by nitric oxide synthase
04/25/2002US20020049200 Use of a methylol-containing compound to treat tumors
04/25/2002US20020049197 Aminoquinazolines and their use as medicaments
04/25/2002US20020049190 Useful in binding nitric oxide; inhibiting tumor growth